{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:42Z","timestamp":1788922122451,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Medication-Related Osteonecrosis of the Jaw (MRONJ), an established side effect of antiresorptive and antiangiogenic medication, could sometimes require surgical intervention, such as decortication. The objectives of this retrospective patient survey study were to evaluate the effect of surgical treated MRONJ on health-related quality of life (QoL) and to assess the awareness of the risk of MRONJ.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The MRONJ-related QoL in both cancer and osteoporosis patients was determined in four different time periods after surgery applying the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30), a modified version of the Module for Head and Neck Cancer (H&amp;N35) and MRONJ-specific questions. In addition the patients\u00b4 awareness of the risk of MRONJ when being prescribed the medication was examined. 65 patients with MRONJ (28 males and 37 females) who underwent surgery of the jaw were included in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In comparison to normative data of the German population cancer and osteoporosis patients showed a reduction in their QoL in general. It was demonstrated that MRONJ causes an even further negative impact, particularly on role and social function. Amongst the MRONJ patients certain factors such as female sex, breast cancer as underlying disease, hypothyroidism, denture, nicotine abuse and multiple surgeries of the MRONJ were associated with worse QoL. The majority of patients suffered from a lack of knowledge regarding the risk of MRONJ when starting antiresorptive or antiangiogenic treatment. Unaware patients manifested worse QoL results and had to undergo more operations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>QoL of MRONJ patients is deteriorated and the number of surgeries and the patients\u00b4 awareness have a significant impact on QoL. In order to reach better awareness amongst both patients, doctors and other health care professionals and to detect MRONJ at an earlier stage, the H&amp;N35 and MRONJ specific questions should be routinely administered to osteoporosis and cancer patients when starting antiresorptive or antiangiogenic treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12903-025-06171-3","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:55:20Z","timestamp":1750514120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["How does medication-related osteonecrosis of the jaw (MRONJ) influence the health-related quality of life after surgery?"],"prefix":"10.1186","volume":"25","author":[{"given":"Oliver","family":"Bissinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Greiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kakoschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Dietrich","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"6","key":"6171_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Min Res. 2008;23(6):826\u201336. https:\/\/doi.org\/10.1359\/jbmr.080205.","journal-title":"J Bone Min Res"},{"issue":"1","key":"6171_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40264-017-0582-6","volume":"41","author":"G Oteri","year":"2018","unstructured":"Oteri G, Trifiro G, Peditto M, Lo Presti L, Marciano I, Giorgianni F, et al. Treatment of Medication-Related osteonecrosis of the jaw and its impact on a patient\u2019s quality of life: A Single-Center, 10-Year experience from Southern Italy. Drug Saf. 2018;41(1):111\u201323. https:\/\/doi.org\/10.1007\/s40264-017-0582-6.","journal-title":"Drug Saf"},{"issue":"25","key":"6171_CR3","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/jco.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Poznak CHV, Bohlke K, Ruggiero SL, et al. Medication-Related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol. 2019;37(25):2270\u201390. https:\/\/doi.org\/10.1200\/jco.19.01186.","journal-title":"J Clin Oncol"},{"issue":"32","key":"6171_CR4","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356\u201362. https:\/\/doi.org\/10.1200\/JCO.2009.21.9584.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6171_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447\u201355. https:\/\/doi.org\/10.1007\/s00520-015-2904-5.","journal-title":"Support Care Cancer"},{"issue":"5","key":"6171_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011;47(5):683\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2010.11.024.","journal-title":"Eur J Cancer"},{"issue":"12","key":"6171_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus Zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823\u20139. https:\/\/doi.org\/10.1097\/JTO.0b013e31826aec2b.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"6171_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19(2):403\u201310. https:\/\/doi.org\/10.1007\/s10147-013-0561-6.","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"6171_CR9","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18(12):2015\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdm370.","journal-title":"Ann Oncol"},{"issue":"1","key":"6171_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of Longer-Interval vs standard dosing of Zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial. JAMA. 2017;317(1):48\u201358. https:\/\/doi.org\/10.1001\/jama.2016.19425.","journal-title":"JAMA"},{"issue":"29","key":"6171_CR11","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26(29):4739\u201345. https:\/\/doi.org\/10.1200\/JCO.2008.16.4707.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6171_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","volume":"11","author":"P Gimsing","year":"2010","unstructured":"Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30\u00a0mg versus 90\u00a0mg on physical function in patients with newly diagnosed multiple myeloma (Nordic myeloma study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11(10):973\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(10)70198-4.","journal-title":"Lancet Oncol"},{"key":"6171_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","volume":"13","author":"RE Coleman","year":"2018","unstructured":"Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, et al. Benefits and risks of adjuvant treatment with Zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04). J Bone Oncol. 2018;13:123\u201335. https:\/\/doi.org\/10.1016\/j.jbo.2018.09.008.","journal-title":"J Bone Oncol"},{"issue":"1","key":"6171_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Min Res. 2015;30(1):3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405.","journal-title":"J Bone Min Res"},{"issue":"2","key":"6171_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243\u201353. https:\/\/doi.org\/10.1016\/j.joms.2009.03.050.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"6171_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Min Res. 2012;27(3):694\u2013701. https:\/\/doi.org\/10.1002\/jbmr.1479.","journal-title":"J Bone Min Res"},{"issue":"11","key":"6171_CR17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","volume":"141","author":"JT Grbic","year":"2010","unstructured":"Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of Zoledronic acid: data from the health outcomes and reduced incidence with Zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010;141(11):1365\u201370. https:\/\/doi.org\/10.14219\/jada.archive.2010.0082.","journal-title":"J Am Dent Assoc"},{"issue":"2","key":"6171_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal fracture trial (PFT). J Bone Min Res. 2012;27(2):243\u201354. https:\/\/doi.org\/10.1002\/jbmr.1494.","journal-title":"J Bone Min Res"},{"issue":"4","key":"6171_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.stomax.2010.07.009","volume":"111","author":"A Barrier","year":"2010","unstructured":"Barrier A, Lescaille G, Rigolet A, Descroix V, Goudot P, Ruhin B. [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. Rev Stomatol Chir Maxillofac. 2010;111(4):196\u2013202. https:\/\/doi.org\/10.1016\/j.stomax.2010.07.009.","journal-title":"Rev Stomatol Chir Maxillofac"},{"issue":"2","key":"6171_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00198-012-2013-y","volume":"24","author":"F Lapi","year":"2013","unstructured":"Lapi F, Cipriani F, Caputi AP, Corrao G, Vaccheri A, Sturkenboom MC, et al. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. Osteoporos Int. 2013;24(2):697\u2013705. https:\/\/doi.org\/10.1007\/s00198-012-2013-y.","journal-title":"Osteoporos Int"},{"issue":"10","key":"6171_CR21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031.","journal-title":"J Oral Maxillofac Surg"},{"key":"6171_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejca.2020.11.022","volume":"144","author":"NML Battisti","year":"2020","unstructured":"Battisti NML, Reed MWR, Herbert E, Morgan JL, Collins KA, Ward SE, et al. Bridging the age gap in breast cancer: impact of chemotherapy on quality of life in older women with early breast cancer. Eur J Cancer. 2020;144:269\u201380. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.022.","journal-title":"Eur J Cancer"},{"issue":"3","key":"6171_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13187-015-0954-5","volume":"32","author":"M Dabrowska-Bender","year":"2017","unstructured":"Dabrowska-Bender M, Sloniewski R, Religioni U, Juszczyk G, Sloniewska A, Staniszewska A. Analysis of quality of life subjective perception by patients treated for prostate Cancer with the EORTC QLQ-C30 questionnaire and QLQ-PR25 module. J Cancer Educ. 2017;32(3):509\u201315. https:\/\/doi.org\/10.1007\/s13187-015-0954-5.","journal-title":"J Cancer Educ"},{"issue":"3","key":"6171_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2478\/raon-2019-0047","volume":"53","author":"SL Ficko","year":"2019","unstructured":"Ficko SL, Pejsa V, Zadnik V. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires. Radiol Oncol. 2019;53(3):337\u201347. https:\/\/doi.org\/10.2478\/raon-2019-0047.","journal-title":"Radiol Oncol"},{"key":"6171_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/pzaa221","author":"M Ponzano","year":"2020","unstructured":"Ponzano M, Rodrigues IB, Hosseini Z, Ashe MC, Butt DA, Chilibeck PD, et al. Progressive resistance training for improving Health-Related outcomes in people at risk of fracture: A systematic review and Meta-Analysis of randomized controlled trials. Phys Ther. 2020. https:\/\/doi.org\/10.1093\/ptj\/pzaa221.","journal-title":"Phys Ther"},{"issue":"9","key":"6171_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115\u20137. https:\/\/doi.org\/10.1016\/s0278-2391(03)00720-1.","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"6171_CR27","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.4317\/jced.53504","volume":"9","author":"A Comas-Calonge","year":"2017","unstructured":"Comas-Calonge A, Figueiredo R, Gay-Escoda C. Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review. J Clin Exp Dent. 2017;9(2):e302\u20137. https:\/\/doi.org\/10.4317\/jced.53504.","journal-title":"J Clin Exp Dent"},{"issue":"5","key":"6171_CR28","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.4317\/medoral.20980","volume":"21","author":"FJ Rodriguez-Lozano","year":"2016","unstructured":"Rodriguez-Lozano FJ, Onate-Sanchez RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral Patol Oral Cir Bucal. 2016;21(5):e595\u2013600. https:\/\/doi.org\/10.4317\/medoral.20980.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"6171_CR29","doi-asserted-by":"crossref","unstructured":"Salvatore L, Ruggiero D, Clinical Professor MD, Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Hofstra North Shore-LIJ School of Medicine, New York Center for Orthognathic and Maxillo- facial Surgery, Lake Success, NY, Thomas B. Dodson D, MPH, Professor and Chair, Associate Dean for Hospital Affairs, University of Washington School of Dentistry, Department of Oral and Maxillofacial Surgery, Seattle, WA, John Fantasia D, Chief, Division of Oral Pathology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, Reginald Goodday P, Department of Oral and Maxillofacial Sciences, Dalhousie University, Halifax, NS, Tara Aghaloo DDS M, PhD, Associate Pro- fessor, Oral and Maxillofacial Surgery, Assistant Dean for Clinical Research, UCLA School of Dentistry, Los Angeles, CA, Bhoomi Mehrotra M, Director et al. Cancer Institute at St. Francis Hospital, Roslyn, NY,. Position Paper Medication-Related Osteonecrosis of the Jaw\u20142014 Update. American Association of Oral and Maxillofacial Surgeons. 2014.","DOI":"10.1016\/j.joms.2014.04.031"},{"issue":"1","key":"6171_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137\u201345. https:\/\/doi.org\/10.1093\/annonc\/mdn526.","journal-title":"Ann Oncol"},{"key":"6171_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177\u201387. https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.007.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"6171_CR32","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1210\/jc.2015-1794","volume":"100","author":"W Sim Ie","year":"2015","unstructured":"Sim Ie W, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR. Declining incidence of Medication-Related osteonecrosis of the jaw in patients with Cancer. J Clin Endocrinol Metab. 2015;100(10):3887\u201393. https:\/\/doi.org\/10.1210\/jc.2015-1794.","journal-title":"J Clin Endocrinol Metab"},{"key":"6171_CR33","doi-asserted-by":"publisher","unstructured":"Catania G, Monaco F, Limberti G, Alessio M, De Martino I, Barile C, et al. Osteonecrosis of the jaws (ONJ) after bisphosphonate treatment in patients with multiple myeloma: decreasing ONJ incidence after adoption of preventive measures. Dent J (Basel). 2016;4(4). https:\/\/doi.org\/10.3390\/dj4040045.","DOI":"10.3390\/dj4040045"},{"issue":"5","key":"6171_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"6171_CR35","first-page":"3527","volume":"32","author":"A Kyrgidis","year":"2012","unstructured":"Kyrgidis A, Triaridis S, Kontos K, Patrikidou A, Andreadis C, Constantinidis J, et al. Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires. Anticancer Res. 2012;32(8):3527\u201334.","journal-title":"Anticancer Res"},{"issue":"2","key":"6171_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/SCS.0000000000004087","volume":"29","author":"G Oteri","year":"2018","unstructured":"Oteri G, De Ponte FS, Runci M, Peditto M, Marciano A, Cicciu M. Oral-Health-Related quality of life after surgical treatment of osteonecrosis of the jaws. J Craniofac Surg. 2018;29(2):403\u20138. https:\/\/doi.org\/10.1097\/SCS.0000000000004087.","journal-title":"J Craniofac Surg"},{"issue":"8","key":"6171_CR37","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s11136-012-0325-1","volume":"22","author":"S Singer","year":"2013","unstructured":"Singer S, Arraras JI, Chie WC, Fisher SE, Galalae R, Hammerlid E, et al. Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. Qual Life Res. 2013;22(8):1927\u201341. https:\/\/doi.org\/10.1007\/s11136-012-0325-1.","journal-title":"Qual Life Res"},{"key":"6171_CR38","unstructured":"Fayers PMAN, Bjordal K, Groenvold M, Curran D, Bottomley A, on, Group botEQoL. The EORTC QLQ-C30 Scoring Manual (3rd Edition). In: Cancer PbEOfRaTo, editor. Brussels2001."},{"issue":"1","key":"6171_CR39","doi-asserted-by":"publisher","first-page":"e52896","DOI":"10.7759\/cureus.52896","volume":"16","author":"AS Assari","year":"2024","unstructured":"Assari AS, Alanazi Y, Mubarak Algharbi E, Abuhabsha A, Alshammry B, Alzahrani A, et al. Awareness of Medication-Related osteonecrosis of the jaws amongst patients on antiresorptive and antiangiogenic medications. Cureus. 2024;16(1):e52896. https:\/\/doi.org\/10.7759\/cureus.52896.","journal-title":"Cureus"},{"issue":"3","key":"6171_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jcms.2011.04.011","volume":"40","author":"JS Bauer","year":"2012","unstructured":"Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S. Awareness and education of patients receiving bisphosphonates. J Cranio-Maxillofacial Surg. 2012;40(3):277\u201382. https:\/\/doi.org\/10.1016\/j.jcms.2011.04.011.","journal-title":"J Cranio-Maxillofacial Surg"},{"issue":"5","key":"6171_CR41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.14219\/jada.archive.2010.0229","volume":"141","author":"Migliorati","year":"2010","unstructured":"Migliorati CA, Mattos K, Palazzolo MJ. How patients\u2019 lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J Am Dent Association. 2010;141(5):562\u20136. https:\/\/doi.org\/10.14219\/jada.archive.2010.0229.","journal-title":"J Am Dent Association"},{"issue":"1","key":"6171_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2458-12-80","volume":"12","author":"K S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen K, Van den Broucke S, Fullam J, Doyle G, Pelikan J, Slonska Z, et al. Health literacy and public health: A systematic review and integration of definitions and models. BMC Public Health. 2012;12(1):80. https:\/\/doi.org\/10.1186\/1471-2458-12-80.","journal-title":"BMC Public Health"},{"issue":"1","key":"6171_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139\u201344. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.139.","journal-title":"J Clin Oncol"},{"key":"6171_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2020.06.002","volume":"137","author":"S Nolte","year":"2020","unstructured":"Nolte S, Waldmann A, Liegl G, Petersen MA, Groenvold M, Rose M, et al. Updated EORTC QLQ-C30 general population norm data for Germany. Eur J Cancer. 2020;137:161\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.002.","journal-title":"Eur J Cancer"},{"key":"6171_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2019.10.031","volume":"125","author":"J Mierzynska","year":"2020","unstructured":"Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, et al. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer. 2020;125:69\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.031.","journal-title":"Eur J Cancer"},{"issue":"12","key":"6171_CR46","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00198-012-2050-6","volume":"23","author":"S Wilson","year":"2012","unstructured":"Wilson S, Sharp CA, Davie MW. Health-related quality of life in patients with osteoporosis in the absence of vertebral fracture: a systematic review. Osteoporos Int. 2012;23(12):2749\u201368. https:\/\/doi.org\/10.1007\/s00198-012-2050-6.","journal-title":"Osteoporos Int"},{"key":"6171_CR47","unstructured":"Neil W, Scott PMF, Neil K, Aaronson A, Groenvold BAGM, Gundy C, Morten MK, Petersen A, Mirjam AG. Group SobotEQoL. EORTC QLQ-C30 reference values. In: Group EQoL, editor.2008."},{"issue":"6","key":"6171_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.bjoms.2020.03.010","volume":"58","author":"J Murphy","year":"2020","unstructured":"Murphy J, Mannion CJ. Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis. Br J Oral Maxillofac Surg. 2020;58(6):619\u201324. https:\/\/doi.org\/10.1016\/j.bjoms.2020.03.010.","journal-title":"Br J Oral Maxillofac Surg"},{"key":"6171_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s10006-020-00927-7","author":"S Moll","year":"2020","unstructured":"Moll S, Mueller S, Meier JK, Reichert TE, Ettl T, Klingelhoffer C. Patients\u2019 quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw. Oral Maxillofac Surg. 2020. https:\/\/doi.org\/10.1007\/s10006-020-00927-7.","journal-title":"Oral Maxillofac Surg"},{"issue":"5","key":"6171_CR50","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","volume":"44","author":"R Fliefel","year":"2015","unstructured":"Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44(5):568\u201385. https:\/\/doi.org\/10.1016\/j.ijom.2015.01.026.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"2","key":"6171_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10006-005-0670-0","volume":"10","author":"MH Abu-Id","year":"2006","unstructured":"Abu-Id MH, Acil Y, Gottschalk J, Kreusch T. [Bisphosphonate-associated osteonecrosis of the jaw]. Mund Kiefer Gesichtschir. 2006;10(2):73\u201381. https:\/\/doi.org\/10.1007\/s10006-005-0670-0.","journal-title":"Mund Kiefer Gesichtschir"},{"issue":"2","key":"6171_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","volume":"61","author":"S Kuroshima","year":"2019","unstructured":"Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J Oral Biosci. 2019;61(2):99\u2013104. https:\/\/doi.org\/10.1016\/j.job.2019.03.005.","journal-title":"J Oral Biosci"},{"issue":"4","key":"6171_CR53","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s13193-021-01426-1","volume":"12","author":"B Zacharia","year":"2021","unstructured":"Zacharia B, Joy J, Subramaniam D, Pai PK. Factors affecting life expectancy after bone metastasis in Adults - Results of a 5-year prospective study. Indian J Surg Oncol. 2021;12(4):759\u201369. https:\/\/doi.org\/10.1007\/s13193-021-01426-1.","journal-title":"Indian J Surg Oncol"},{"issue":"12","key":"6171_CR54","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ijom.2011.09.003","volume":"40","author":"CM Speksnijder","year":"2011","unstructured":"Speksnijder CM, van der Bilt A, van der Glas HW, Koole R, Merkx MA. Tongue function in patients treated for malignancies in tongue and\/or floor of mouth; a one year prospective study. Int J Oral Maxillofac Surg. 2011;40(12):1388\u201394. https:\/\/doi.org\/10.1016\/j.ijom.2011.09.003.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"6171_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29573","author":"MG Bulbul","year":"2021","unstructured":"Bulbul MG, Wu M, Lin D, Emerick K, Deschler D, Richmon J, et al. Prediction of speech, swallowing, and quality of life in oral cavity Cancer patients: A pilot study. Laryngoscope. 2021. https:\/\/doi.org\/10.1002\/lary.29573.","journal-title":"Laryngoscope"},{"issue":"4","key":"6171_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcms.2020.02.017","volume":"48","author":"J Vanpoecke","year":"2020","unstructured":"Vanpoecke J, Verstraete L, Smeets M, Ferri J, Nicot R, Politis C. Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and Conservative surgical approaches versus an aggressive surgical intervention: A systematic review. J Craniomaxillofac Surg. 2020;48(4):435\u201343. https:\/\/doi.org\/10.1016\/j.jcms.2020.02.017.","journal-title":"J Craniomaxillofac Surg"},{"issue":"4","key":"6171_CR57","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","volume":"66","author":"JH Wessel","year":"2008","unstructured":"Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008;66(4):625\u201331. https:\/\/doi.org\/10.1016\/j.joms.2007.11.032.","journal-title":"J Oral Maxillofac Surg"},{"issue":"12","key":"6171_CR58","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.12968\/bjcn.2003.8.Sup6.12554","volume":"8","author":"L Whiteford","year":"2003","unstructured":"Whiteford L, Nicotine. CO and HCN: the detrimental effects of smoking on wound healing. Br J Community Nurs. 2003;8(12):S22\u20136. https:\/\/doi.org\/10.12968\/bjcn.2003.8.Sup6.12554.","journal-title":"Br J Community Nurs"},{"key":"6171_CR59","doi-asserted-by":"publisher","unstructured":"Silverstein P. Smoking and wound healing. Am J Med. 1992;93(1A):22S-4S. https:\/\/doi.org\/10.1016\/0002-9343(92)90623-j","DOI":"10.1016\/0002-9343(92)90623-j"},{"issue":"2","key":"6171_CR60","first-page":"155","volume":"73","author":"WJ Millar","year":"2007","unstructured":"Millar WJ, Locker D. Smoking and oral health status. J Can Dent Assoc. 2007;73(2):155.","journal-title":"J Can Dent Assoc"},{"key":"6171_CR61","unstructured":"Wahnschaff F. Gesundheitsbezogene lebensqualit\u00e4t Nach autologem fibulatransfer Zur rekonstruktion des Kiefers klinik f\u00fcr Kiefer- und gesichtschirurgie L\u00fcbeck. Universit\u00e4t zu L\u00fcbeck; 2010."},{"issue":"5","key":"6171_CR62","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdr435.","journal-title":"Ann Oncol"},{"issue":"4","key":"6171_CR63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"A Barasch","year":"2011","unstructured":"Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res. 2011;90(4):439\u201344. https:\/\/doi.org\/10.1177\/0022034510397196.","journal-title":"J Dent Res"},{"issue":"6","key":"6171_CR64","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg. 2015;43(6):847\u201354. https:\/\/doi.org\/10.1016\/j.jcms.2015.03.039.","journal-title":"J Craniomaxillofac Surg"},{"key":"6171_CR65","doi-asserted-by":"publisher","unstructured":"Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative management of Medication-Related osteonecrosis of the jaws (MRONJ): A retrospective cohort study. Antibiot (Basel). 2021;10(2). https:\/\/doi.org\/10.3390\/antibiotics10020195.","DOI":"10.3390\/antibiotics10020195"},{"issue":"1","key":"6171_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-014-2309-x","volume":"23","author":"G Hechmati","year":"2015","unstructured":"Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, et al. Patients\u2019 preferences for bone metastases treatments in France, Germany and the united Kingdom. Support Care Cancer. 2015;23(1):21\u20138. https:\/\/doi.org\/10.1007\/s00520-014-2309-x.","journal-title":"Support Care Cancer"},{"issue":"6","key":"6171_CR67","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jsps.2020.05.004","volume":"28","author":"A Al Abdullateef","year":"2020","unstructured":"Al Abdullateef A, Alhareky MS. Awareness among patient at risk of developing medication related osteonecrosis of the jaw (MRONJ) - A primary prevention strategy. Saudi Pharm J. 2020;28(6):771\u20138. https:\/\/doi.org\/10.1016\/j.jsps.2020.05.004.","journal-title":"Saudi Pharm J"},{"issue":"9","key":"6171_CR68","doi-asserted-by":"publisher","first-page":"300060520955066","DOI":"10.1177\/0300060520955066","volume":"48","author":"A El-Ma\u2019aita","year":"2020","unstructured":"El-Ma\u2019aita A, Da\u2019as N, Al-Hattab M, Hassona Y, Al-Rabab\u2019ah M, Al-Kayed MA. Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users. J Int Med Res. 2020;48(9):300060520955066. https:\/\/doi.org\/10.1177\/0300060520955066.","journal-title":"J Int Med Res"},{"issue":"1","key":"6171_CR69","doi-asserted-by":"publisher","first-page":"e0297500","DOI":"10.1371\/journal.pone.0297500","volume":"19","author":"N Supanumpar","year":"2024","unstructured":"Supanumpar N, Pisarnturakit PP, Charatcharoenwitthaya N, Subbalekha K. Physicians\u2019 awareness of medication-related osteonecrosis of the jaw in patients with osteoporosis. PLoS ONE. 2024;19(1):e0297500. https:\/\/doi.org\/10.1371\/journal.pone.0297500.","journal-title":"PLoS ONE"},{"issue":"1","key":"6171_CR70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12903-016-0290-0","volume":"16","author":"JW Kim","year":"2016","unstructured":"Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical Doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016;16(1):92. https:\/\/doi.org\/10.1186\/s12903-016-0290-0.","journal-title":"BMC Oral Health"},{"issue":"3","key":"6171_CR71","doi-asserted-by":"publisher","first-page":"e024376","DOI":"10.1136\/bmjopen-2018-024376","volume":"9","author":"A Sturrock","year":"2019","unstructured":"Sturrock A, Preshaw PM, Hayes C, Wilkes S. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open. 2019;9(3):e024376. https:\/\/doi.org\/10.1136\/bmjopen-2018-024376.","journal-title":"BMJ Open"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-06171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-025-06171-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-06171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:55:23Z","timestamp":1750514123000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-025-06171-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6171"],"URL":"https:\/\/doi.org\/10.1186\/s12903-025-06171-3","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent from the patient to participate in the study had been obtained. The study was approved by the Ethical Committee of the Technische Universitaet Muenchen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained written consent from the patients before publishing this information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"951"}}